跳至主要内容
临床试验/DRKS00025056
DRKS00025056已完成4 期

Treatment of wound healing disorders in patients with diabetic foot syndrome caused by diabetic neuropathy (neuropathic foot), or diabetic angiopathy (gangrene) with the medical device TOXAPREVENT SKIN® skin powder and early detection of a possible wound infection by MEANS of VOC analysis by MCC-IMS - MANC-MCC-IMS-202005

FROXIMUN AG0 个研究点目标入组 50 人开始时间: 2021年4月14日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
FROXIMUN AG
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 90 Years(—)
性别
All

入选标准

  • Indication according to the target
  • Healthy skin areas present as a control area
  • Patients with diabetic neuropathy (neuropathic foot), or diabetic angiopathy (gangrene)

排除标准

  • Severe HKE (cardiovascular disease)
  • other primarily chronic skin diseases
  • Higher degree of liver and/or renal failure
  • higher-grade dementia/ Delir
  • Septic disease
  • Lack of compliance
  • Lack of consent

研究者

发起方
FROXIMUN AG

相似试验